← Eichor
Study identifier: NCT05260177 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Condition: Alzheimer's Disease  ·  Sponsor: Zealand University Hospital

PhaseNA
Planned participants62
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

The ALZLIGHT STAGE III Study is a continuation of the ALZLIGHT Pilot - Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System. As with the first two stages, this study will examine whether entrainment of 40 Hz neural oscillation by novel 40 Hz Invisible Spectral Flicker is a potential therapy for Alzheimer's Disease. In order to examine this, 62 patients with mild to moderate Alzheimer's Disease will be recruited. The patients will be exposed to the Non-Invasive Light Therapy System for 1 hour a day for 6 months. The effect will be measured by a combination of electroencephalography, cognitive testing, functional magnetic resonance imaging, magnetic resonance spectroscopy and actigraphy.

This description comes directly from the study's public registry record.

Talk to the study team

Peter Høgh, MD, Phd  ·  47322809  ·  phh@regionsjaelland.dk

Maibritt Horning, MSc  ·  +45 81949649  ·  maibho@regionsjaelland.dk

Always discuss trial participation with your own doctor first.

Locations (1)

Zealand University HospitalRoskilde, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05260177